{"streaming_server":"rtmp:\/\/s2svek4dh1hfyu.cloudfront.net\/cfx\...

.

Phylogica Limited (ASX:PYC) CFO and VP Corporate Development, Nick Woolf, details the peptide drug discovery companies latest collaborations with Pfizer, Roche and MedImmune, the biologics unit of AstraZeneca. Phylogica has just successfully finished the first stage of its collaboration with Pfizer and identified several peptides from its libraries that will be further evaluated by Pfizer.

 

Mr Woolf outlines the company’s plans for future collaborations and provides an update on talks with other pharma companies. Phylogica is currently discussing projects and collaborations with potential partners and has multiple term sheets under discussion. The company says it is on track to deliver on its guidance, to sign three new partnerships before June 20, 2012, and is targeting to close a new collaboration by the end of FY2011.   

 

Mr Woolf shares the details of Phylogica’s recent capital raising, including where the funds will be going and Phylogica’s 12 month outlook. Phylogica is also looking to scale up its in-house infrastructure, boosting up its scientific team and purchasing new equipment and developing in-house programmes, to prepare for the anticipated deal flow.